Following the South African government's recent approval of a new intellectual property policy that includes elements aimed at preserving access to medical products that are increasing in popularity among developing countries, the research-based pharmaceutical industry had a few general comments. The message: the policy incorporates some of their concerns but is wrong on "evergreening" patents, and could harm industry, which is "the goose that lays the golden egg." Continue reading ->
Falsified and substandard medical products continue to be a global concern, and how those products are characterised is important to avoid confusion, particularly with intellectual property rights infringement. A panel convened by Brazil, India and South Africa yesterday at the World Trade Organization looked at the implications of a new definition of such products at the neighbouring World Health Organization. Continue reading ->
Ten years after the adoption of a World Health Organization plan of action meant to stimulate innovation for diseases that disproportionately affect developing countries, and with very little to show for it since, delegates at the World Health Assembly this week agreed to a number of recommendations to reinvigorate the effort. How to finance the implementation of those recommendations, however, is unclear. Continue reading ->
The World Health Assembly this week agreed on a roadmap to be designed by the World Health Organization in consultation with member states to facilitate access to medicines and vaccines, including actions and activities for the period 2019-2023. If everyone agrees access to medicines and vaccines is indispensable for universal health coverage, views are still divided when it comes to intellectual property rights. The ranks of strong proponents of IP resulting in high prices are however thinning. The United States remains unshakeable, criticising compulsory licences used by countries to ensure affordable medicines are available. Continue reading ->
Dr Tedros Adhanom Ghebreyesus, WHO Director-General in his inaugural speech at the World Health Assembly this week, explained that partnerships are a key strategy for the WHO to ensuring healthy lives and promoting well-being for all at all ages. He added that the WHO is engaging with the private sector as a crucial partner in achieving health for all. Thomas Cueni, IFPMA’s Director General, in an interview with Health Policy Watch on the occasion of the IFPMA’s 50-year anniversary, explains how the research-based biopharmaceutical industry together with IFPMA have contributed to the huge strides in health progress over 50 years. He explains the major leaps forward, setbacks and mistakes, as well as how industry is part of the solution, as "do-ers" and partners in global health progress. Cueni also talks about pricing and cost of R&D. Continue reading ->
US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading ->
The World Health Organization celebrated its 70th anniversary last month. Since the inception of the organisation, the world has changed, and so have its challenges. The global rise of non-communicable diseases is one example of those challenges, as well as the escalating prices of new medicines and chronic access issues in many countries. The annual World Health Assembly will open on 21 May with an ambitious new General Programme of Work for 2019-2023, which promises 1 billion more people under universal health coverage. Continue reading ->
Research collaborations between institutions in the North and institutions in the South often show a scientific and power imbalance. In the context of growing concerns about this issue, initiatives are being developed to increase fairness in research partnerships. In particular, the Research Fairness Initiative, providing a reporting system for institutions is gaining traction, according to speakers at the Geneva Health Forum this week. Continue reading ->